Company intelligence / Profile preview

Hemera Biosciences

Newton, Massachusetts, United Statesjnj.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Phase 1 study of HMR59 for patients with geographic atrophy is complete. A second Phase 1 study exploring HMR59 in patients with wet-AMD was conducting follow-up visits to evaluate long-term safety as of the acquisition date[1][4].

Therapeutic areas: Ophthalmology
Modalities: Gene therapy
Industry: Biotech

Drug pipeline

1 asset

HMR59

Pre-clinical

Indications: Geographic atrophy secondary to age-related macular degeneration, Late-stage age-related macular degeneration

Partnerships

Acquired by Janssen Pharmaceuticals (Johnson & Johnson) in December 2020

Beyond the preview

Go deeper on Hemera Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemera Biosciences.

Explore the full profile